SEC
ADMA icon

Seven Eight Capital’s ADMA Biologics ADMA Stock Holding History

Seven Eight Capital’s Portfolio ADMA Stock Details ADMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-50,971
Closed -$1.02M – 11
2024
Q3 		$1.02M Sell
50,971
-127,232
-71% -$1.98M 0.09% 386
2024
Q2 		$1.99M Buy
+178,203
New +$1.49M 0.21% 136

Other funds holding ADMA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Seven Eight Capital's ADMA Position: Q4 2024 in Review

Seven Eight Capital sold out of ADMA Biologics (ADMA) in Q4 2024, closing a stake of 50,971 shares — an estimated $1.02M sold.

Seven Eight Capital first reported a position in ADMA in Q2 2024 and held it in 2 quarters. The position peaked at $1.99M in Q2 2024. 321 funds tracked by Wall St. Rank hold ADMA as of Q4 2024.

  • Seven Eight Capital reported no remaining ADMA Biologics position as of Q4 2024 after selling out during the quarter.
  • Seven Eight Capital sold 50,971 ADMA Biologics shares in Q4 2024, an estimated $1.02M.
  • Seven Eight Capital first reported a position in ADMA Biologics in Q2 2024 and held it in 2 quarters.
  • Seven Eight Capital's ADMA Biologics position peaked at $1.99M in Q2 2024.
  • 321 funds tracked by Wall St. Rank held ADMA Biologics as of Q4 2024.

Based on Seven Eight Capital's 13F filing for Q4 2024.